Xgene Pharmaceutical Inc. develops multimodal conjugated prodrugs that combine two established analgesic agents into a single molecule using proprietary linker chemistry, creating dual‑acting compounds with optimized pharmacokinetics and reduced systemic toxicity. Their lead candidate, XG005, simultaneously inhibits COX and modulates peripheral α2δ calcium channels to provide broader pain relief for neuropathic, nociceptive, and centrally sensitized pain, with Phase II/III data showing significant efficacy and lower opioid use. The company partners with pharmaceutical licensees to commercialize these non‑opioid analgesics worldwide.
Funding
$60M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with chronic and acute pain often rely on opioid medications, which carry risks of addiction, gastrointestinal complications, and central nervous system side effects, while existing non‑opioid options provide limited efficacy across the multiple mechanisms that drive neuropathic, nociceptive, and centrally sensitized pain.
Solution
Xgene Pharmaceutical develops multimodal conjugated prodrugs that combine two well‑characterized analgesic agents into a single molecule linked by proprietary chemistry. The linker modifies absorption, pharmacokinetics, and metabolism, enabling targeted delivery and reduced systemic toxicity. Their lead candidate, XG005, simultaneously inhibits cyclooxygenase and modulates peripheral α2δ calcium channels, addressing both inflammatory and neuropathic pain pathways. Clinical data from Phase II/III trials show significant pain reduction, improved joint function, and a marked decrease in opioid rescue medication use. Xgene advances these candidates through late‑stage development and partners with regional licensees to commercialize non‑opioid analgesics in key markets.
Target Audience
Primary customers are pharmaceutical partners and contract manufacturers seeking novel non‑opioid analgesics, as well as clinicians and health systems treating patients with acute postoperative pain, osteoarthritis, and mixed neuropathic‑inflammatory pain conditions.
Features
- Proprietary linker technology that creates dual‑acting conjugates with distinct pharmacokinetic profiles compared to parent drugs
- Multimodal mechanism of action (COX inhibition + peripheral α2δ calcium‑channel modulation) for broader pain coverage
- Demonstrated lower toxicity and superior efficacy in preclinical models of neuropathic and inflammatory pain
- Positive Phase II/III clinical outcomes for XG005 in post‑surgical and osteoarthritis pain, including reduced opioid rescue use
- Flexible licensing model enabling regional partners to develop, manufacture, and commercialize products while Xgene retains worldwide rights outside licensed territories
- Scalable oral tablet and capsule formulations designed for convenient administration in outpatient and hospital settings